OneMedNet Corporation (ONMD) — AI Stock Analysis

OneMedNet Corporation provides clinical imaging solutions through its iRWD platform, utilizing AI to de-identify, search, and curate imaging data. The company partners with medical and academic research institutions to advance medical research, discovery, and diagnostics.

Company Overview

TL;DR:

OneMedNet Corporation pioneers AI-driven clinical imaging solutions, offering iRWD to securely de-identify and curate data for medical research, positioning itself as a key enabler for advancements in life sciences and diagnostics with a market cap of $0.02 billion.

About ONMD

OneMedNet Corporation, headquartered in Eden Prairie, Minnesota, is a healthcare information services company focused on providing clinical imaging solutions. The company's core offering is iRWD, a platform that leverages artificial intelligence to securely de-identify, search, and curate imaging data. This technology is designed to facilitate medical and academic research by providing a streamlined and secure method for accessing and utilizing clinical imaging data. OneMedNet partners with a network of medical and academic research institutions, enabling them to accelerate progress in medical research, discovery, and diagnostics across various life science fields. The iRWD platform addresses the critical need for secure and efficient data sharing in the healthcare industry, helping to bridge the gap between data accessibility and patient privacy. With a focus on innovation and collaboration, OneMedNet aims to drive advancements in medical research and improve patient outcomes through its cutting-edge imaging solutions.

Investment Thesis

OneMedNet Corporation presents a speculative investment opportunity within the healthcare information services sector. The company's iRWD platform, leveraging AI for clinical imaging data curation, addresses a growing need for secure and efficient data sharing in medical research. While the company's negative profit margin of -411.1% and gross margin of -151.3% raise concerns, the potential for growth lies in expanding its partner network and increasing adoption of its iRWD platform. The company's beta of 1.14 suggests higher volatility compared to the market. Successful execution of its growth strategies and achieving profitability are critical for realizing value. Investors should carefully consider the risks associated with the company's financial performance and market position before investing.

Industry Context

OneMedNet Corporation operates within the healthcare information services industry, a sector experiencing rapid growth driven by the increasing adoption of digital health technologies and the need for efficient data management. The market is characterized by intense competition, with companies vying to provide innovative solutions for data sharing, analysis, and security. OneMedNet's iRWD platform positions it within the niche of AI-driven clinical imaging data curation, catering to the specific needs of medical and academic research institutions. The company competes with other players in the healthcare IT space, including those focused on data analytics, cloud-based solutions, and medical imaging software. The increasing demand for personalized medicine and the growing volume of healthcare data are key trends shaping the industry landscape.

Medical - Healthcare Information Services

Healthcare

Growth Opportunities

Expanding the iRWD Platform to New Geographies: OneMedNet can pursue geographic expansion by targeting medical research institutions and healthcare providers in new regions. The global market for healthcare IT solutions is projected to reach $390.7 billion by 2028, presenting a significant opportunity for OneMedNet to increase its market share. This expansion could be achieved through strategic partnerships, direct sales efforts, and participation in industry conferences. Timeline: 2-3 years.
Developing New AI-Powered Features for iRWD: OneMedNet can enhance its iRWD platform by incorporating new AI-powered features, such as advanced image analysis, predictive analytics, and personalized medicine applications. The AI in healthcare market is expected to reach $95.7 billion by 2030, driven by the increasing demand for AI-based solutions in diagnostics, treatment planning, and drug discovery. This would require investment in research and development and collaboration with AI experts. Timeline: 1-2 years.
Strategic Partnerships with Pharmaceutical Companies: OneMedNet can forge strategic partnerships with pharmaceutical companies to leverage its iRWD platform for drug discovery and clinical trials. The pharmaceutical industry is increasingly relying on real-world data and AI to accelerate drug development and improve clinical trial outcomes. By providing secure and curated imaging data, OneMedNet can help pharmaceutical companies identify potential drug targets, optimize clinical trial designs, and monitor treatment response. Timeline: 1-2 years.
Offering iRWD as a Cloud-Based Solution: Transitioning iRWD to a cloud-based platform can enhance its scalability, accessibility, and cost-effectiveness. The cloud computing in healthcare market is projected to reach $76.9 billion by 2027, driven by the increasing adoption of cloud-based solutions for data storage, analytics, and application deployment. This would involve migrating the iRWD platform to a cloud infrastructure and offering it as a software-as-a-service (SaaS) solution. Timeline: 1 year.
Targeting Smaller Research Institutions and Clinics: OneMedNet can expand its customer base by targeting smaller research institutions and clinics that may not have the resources to develop their own data curation solutions. This would involve tailoring the iRWD platform to meet the specific needs of smaller organizations and offering flexible pricing models. The market for healthcare IT solutions among smaller providers is growing, driven by the increasing adoption of electronic health records and the need for data-driven decision-making. Timeline: Ongoing.

Market Cap of $0.02 billion reflects its small size and growth potential in the clinical imaging solutions market.
P/E Ratio of -13.22 indicates the company is currently not profitable, suggesting a high-risk, high-reward investment.
Negative Profit Margin of -411.1% highlights significant challenges in achieving profitability and operational efficiency.
Gross Margin of -151.3% indicates the company's cost of revenue exceeds its revenue, requiring strategic adjustments.
Beta of 1.14 suggests the stock is more volatile than the market, potentially offering higher returns but also greater risk.

What They Do

Provides clinical imaging solutions to healthcare providers and research institutions.
Offers iRWD, an AI-powered platform for de-identifying, searching, and curating imaging data.
Facilitates secure data sharing for medical research and discovery.
Enables advancements in diagnostics and treatment planning.
Partners with medical and academic institutions to accelerate research.
Utilizes AI to improve the efficiency and accuracy of data analysis.
Supports the development of personalized medicine approaches.

Business Model

Offers iRWD platform as a service to medical and academic research institutions.
Generates revenue through subscription fees or licensing agreements.
Potentially charges for data curation and analysis services.
May explore partnerships with pharmaceutical companies for drug discovery applications.

Medical research institutions
Academic research institutions
Hospitals and clinics
Pharmaceutical companies (potential)

Proprietary AI-powered iRWD platform
Established network of medical and academic research partners
Expertise in secure data de-identification and curation
First-mover advantage in the niche of AI-driven clinical imaging data solutions

Catalysts

Ongoing: Expansion of the iRWD platform to new medical research institutions.
Upcoming: Development and launch of new AI-powered features for iRWD in Q3 2026.
Ongoing: Strategic partnerships with pharmaceutical companies for drug discovery applications.
Upcoming: Transition of iRWD to a cloud-based platform by Q4 2026.

Risks

Ongoing: Negative profit and gross margins pose a significant threat to financial sustainability.
Potential: Intense competition from larger, more established healthcare IT providers could limit market share.
Potential: Evolving data privacy regulations may require costly compliance measures.
Potential: Cybersecurity risks associated with data sharing could damage reputation and lead to financial losses.
Ongoing: Reliance on a single product (iRWD) makes the company vulnerable to market shifts and technological advancements.

Strengths

Proprietary iRWD platform with AI capabilities
Focus on secure data de-identification and curation
Partnerships with medical and academic institutions
Potential for scalability through cloud-based deployment

Weaknesses

Negative profit and gross margins
Limited market presence and brand recognition
Reliance on a single product (iRWD)
Small number of employees

Opportunities

Expanding into new geographic markets
Developing new AI-powered features for iRWD
Forging strategic partnerships with pharmaceutical companies
Targeting smaller research institutions and clinics

Threats

Intense competition from established healthcare IT providers
Evolving data privacy regulations
Potential for technological obsolescence
Cybersecurity risks associated with data sharing

Competitors & Peers

BioTelemetry Inc — Offers remote cardiac monitoring services. — (BEAT)
Fortress Biotech Inc — Focuses on acquiring, developing, and commercializing pharmaceutical products. — (FBIO)
MedAvail Holdings Inc — Provides pharmacy services through its MedAvail MedCenters. — (MDAI)
NRx Pharmaceuticals Inc — Develops novel therapeutics for the treatment of central nervous system disorders. — (NRXP)
OstiSense Inc. — Develops medical sensing technologies. — (OSTX)

Key Metrics

Price: $0.80 (+5.67%)
Market Cap: $27
Volume: NaN
MoonshotScore: 45/100

Company Profile

CEO: Aaron Green
Headquarters: Eden Prairie, MN, US
Employees: 22
Founded: 2021

AI Insight

OneMedNet Corporation provides clinical imaging solutions through its iRWD platform. iRWD utilizes AI to de-identify, search, and curate imaging data for medical and academic research institutions.

Questions & Answers

What does OneMedNet Corporation do?

OneMedNet Corporation specializes in providing clinical imaging solutions through its iRWD platform. This platform utilizes artificial intelligence to securely de-identify, search, and curate imaging data, catering primarily to medical and academic research institutions. By facilitating secure and efficient data sharing, OneMedNet enables advancements in medical research, discovery, and diagnostics. The company's focus on AI-driven data curation positions it as a key enabler for personalized medicine and improved patient outcomes, addressing the growing need for secure and accessible healthcare data.

Is ONMD stock a good buy?

ONMD stock presents a high-risk, high-reward investment opportunity. While the company's negative profit margin of -411.1% and gross margin of -151.3% raise concerns, the potential for growth in the healthcare information services sector is significant. The company's iRWD platform offers a unique solution for secure data sharing, but its success depends on expanding its customer base and achieving profitability. Investors should carefully weigh the risks and potential rewards before considering ONMD stock, considering its volatile nature indicated by a beta of 1.14.

What are the main risks for ONMD?

OneMedNet faces several key risks, including its current financial performance with negative profit and gross margins, indicating a struggle for profitability. Intense competition from larger, more established healthcare IT providers poses a threat to market share. Evolving data privacy regulations could require significant investments in compliance. Cybersecurity risks associated with data sharing could lead to reputational damage and financial losses. The company's reliance on a single product, iRWD, makes it vulnerable to market shifts and technological obsolescence, requiring continuous innovation and diversification.

Is ONMD a good investment right now?

Use the AI score and analyst targets on this page to evaluate OneMedNet Corporation (ONMD). Our analysis considers fundamentals, technicals, and market sentiment to help you decide.

What is the MoonshotScore for ONMD?

The MoonshotScore is a proprietary 0-100 AI rating that evaluates OneMedNet Corporation across multiple dimensions including financial health, growth trajectory, and risk factors.

Where can I find ONMD financial statements?

OneMedNet Corporation financial data including revenue, earnings, and balance sheet metrics are available in the Financials tab on this page, sourced from institutional-grade data providers.

What do analysts say about ONMD?

Analyst consensus targets and ratings for OneMedNet Corporation are shown in the analysis section. These are aggregated from major Wall Street firms and updated regularly.

How volatile is ONMD stock?

Check the beta and historical price range on this page to assess OneMedNet Corporation's volatility relative to the broader market.